Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA: A Cancer Journal for Clinicians. 2018; 68: 394-424

A preventable cancer.

Nature. 2014; 516: S2-S3Kamangar F. Dores G.M. Anderson W.F.

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

J Clin Oncol. 2006; 24: 2137-2150Yang D. Hanna D.L. Usher J. LoCoco J. Chaudhari P. Lenz H.-J. Setiawan V.W. El-Khoueiry A.

Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis.

Cancer. 2014; 120: 3707-3716Chang M.-H. You S.-L. Chen C.-J. Liu C.-J. Lee C.-M. Lin S.-M. Chu H.-C. Wu T.-C. Yang S.-S. Kuo H.-S. Chen D.-S. Taiwan Hepatoma Study Group

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

J Natl Cancer Inst. 2009; 101: 1348-1355Llovet J.M. Zucman-Rossi J. Pikarsky E. Sangro B. Schwartz M. Sherman M. Gores G.

Hepatocellular carcinoma.

Nat Rev Dis Primers. 2016; 2: 16018Altekruse S.F. McGlynn K.A. Reichman M.E.

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

J Clin Oncol. 2009; 27: 1485-1491

Management of hepatocellular carcinoma: An update.

Hepatology. 2011; 53: 1020-1022Marrero J.A. Feng Z. Wang Y. Nguyen M.H. Befeler A.S. Roberts L.R. Reddy K.R. Harnois D. Llovet J.M. Normolle D. Dalhgren J. Chia D. Lok A.S. Wagner P.D. Srivastava S. Schwartz M.

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Gastroenterology. 2009; 137: 110-118Kudo A. Matsumura S. Ban D. Irie T. Ochiai T. Tanaka S. Arii S. Tanabe M.

Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function?.

Hepatol Res. 2014; 44: E437-446Nakazawa T. Hidaka H. Takada J. Okuwaki Y. Tanaka Y. Watanabe M. Shibuya A. Minamino T. Kokubu S. Koizumi W.

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Eur J Gastroenterol Hepatol. 2013; 25: 683-689Cohen J.D. Li L. Wang Y. Thoburn C. Afsari B. Danilova L. et al.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Science. 2018; 359: 926-930Crowley E. Di Nicolantonio F. Loupakis F. Bardelli A.

Liquid biopsy: monitoring cancer-genetics in the blood.

Nat Rev Clin Oncol. 2013; 10: 472-484Phallen J. Sausen M. Adleff V. Leal A. Hruban C. White J. et al.

Direct detection of early-stage cancers using circulating tumor DNA.

Sci Transl Med. 2017; 9Jung K. Fleischhacker M. Rabien A.

Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

Clin Chim Acta. 2010; 411: 1611-1624Schwarzenbach H. Hoon D.S.B. Pantel K.

Cell-free nucleic acids as biomarkers in cancer patients.

Nature Reviews Cancer. 2011; 11: 426-437Chan K.C.A. Jiang P. Zheng Y.W.L. Liao G.J.W. Sun H. Wong J. Siu S.S.N. Chan W.C. Chan S.L. Chan A.T.C. Lai P.B.S. Chiu R.W.K. Lo Y.M.D.

Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.

Clin Chem. 2013; 59: 211-224Chan K.C.A. Jiang P. Chan C.W.M. Sun K. Wong J. Hui E.P. Chan S.L. Chan W.C. Hui D.S.C. Ng S.S.M. Chan H.L.Y. Wong C.S.C. Ma B.B.Y. Chan A.T.C. Lai P.B.S. Sun H. Chiu R.W.K. Lo Y.M.D.

Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.

Proc Natl Acad Sci U S A. 2013; 110: 18761-18768Ji X. Li J. Huang Y. Sung P.-L. Yuan Y. Liu Q. et al.

Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests.

Genetics in Medicine. 2019; : 1Leary R.J. Sausen M. Kinde I. Papadopoulos N. Carpten J.D. Craig D. O’Shaughnessy J. Kinzler K.W. Parmigiani G. Vogelstein B. Diaz L.A. Velculescu V.E.

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.

Sci Transl Med. 2012; 4: 162ra154Cristiano S. Leal A. Phallen J. Fiksel J. Adleff V. Bruhm D.C. et al.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Nature. 2019; 570: 385-389Mouliere F. Chandrananda D. Piskorz A.M. Moore E.K. Morris J. Ahlborn L.B. et al.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Sci Transl Med. 2018; 10Jiang P. Chan C.W.M. Chan K.C.A. Cheng S.H. Wong J. Wong V.W.-S. Wong G.L.H. Chan S.L. Mok T.S.K. Chan H.L.Y. Lai P.B.S. Chiu R.W.K. Lo Y.M.D.

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.

Proc Natl Acad Sci USA. 2015; 112: E1317-1325Liu M.C. Oxnard G.R. Klein E.A. Swanton C. Seiden M.V. Liu M.C. et al.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Annals of Oncology. 2020; 31: 745-759Xu R.-H. Wei W. Krawczyk M. Wang W. Luo H. Flagg K. et al.

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.

Nat Mater. 2017; 16: 1155-1161McBride D.J. Orpana A.K. Sotiriou C. Joensuu H. Stephens P.J. Mudie L.J. Hämäläinen E. Stebbings L.A. Andersson L.C. Flanagan A.M. Durbecq V. Ignatiadis M. Kallioniemi O. Heckman C.A. Alitalo K. Edgren H. Futreal P.A. Stratton M.R. Campbell P.J.

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.

Genes Chromosomes Cancer. 2010; 49: 1062-1069Kan Z. Zheng H. Liu X. Li S. Barber T.D. Gong Z. et al.

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.

Genome Res. 2013; 23: 1422-1433Scheinin I. Sie D. Bengtsson H. van de Wiel M.A. Olshen A.B. van Thuijl H.F. van Essen H.F. Eijk P.P. Rustenburg F. Meijer G.A. Reijneveld J.C. Wesseling P. Pinkel D. Albertson D.G. Ylstra B.

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.

Genome Res. 2014; 24: 2022-2032Mermel C.H. Schumacher S.E. Hill B. Meyerson M.L. Beroukhim R. Getz G.

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Genome Biol. 2011; 12: R41Liu S. Huang S. Chen F. Zhao L. Yuan Y. Francis S.S. et al.

Genomic Analyses from Non-invasive Prenatal Testing Reveal Genetic Associations, Patterns of Viral Infections, and Chinese Population History.

Cell. 2018; 175 (e14): 347-359

Avoiding common pitfalls in machine learning omic data science.

Nat Mater. 2019; 18: 422-427Snyder M.W. Kircher M. Hill A.J. Daza R.M. Shendure J.

Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.

Cell. 2016; 164: 57-68Tanaka M. Katayama F. Kato H. Tanaka H. Wang J. Qiao Y.L. Inoue M.

Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures.

J Epidemiol. 2011; 21: 401-416Lenaerts L. Vandenberghe P. Brison N. Che H. Neofytou M. Verheecke M. Leemans L. Maggen C. Dewaele B. Dehaspe L. Vanderschueren S. Dierickx D. Vandecaveye V. Amant F. Vermeesch J.R.

Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.

Ann Oncol. 2019; 30: 85-95